[Form 6-K TABLE OF CONTENTS Page Page 3 Press Release Regarding Earnings Results for the Fourth Quarter and Year Ended December 31, 2009, dated February 25, 2010 NETEASE.COM, INC. /s/ Onward Choi Name: Onward Choi Title: Acting Chief Financial Officer Press Release Contact for Media and Investors: Brandi Piacente Investor Relations]
[Biostar Pharmaceuticals, Inc. Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operating Income of $16 – $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) Biostar expects to report gross margin for 2009 of approximately 71%, an increase of 1200 basis-points compared to 59% in 2008. Management anticipates unaudited operating income, excluding non-cash charges, of]
[Table of Contents Form 6-K TABLE OF CONTENTS Page Page 3 Press Release Regarding Earnings Results for the Fourth Quarter and Year Ended December 31, 2009, dated February 25, 2010 Table of Contents NETEASE.COM, INC. /s/ Onward Choi Name: Onward Choi Title: Acting Chief Financial Officer Table of Contents Press Release]
[China Sunergy Co., Ltd. Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G84831 105** (CUSIP Number) December 31, 2009 [] Rule 13d-1(b) [ ] Rule 13d-1(c) [X ] Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of]
[Table of Contents Form 6-K TABLE OF CONTENTS Page Page 3 Press Release Regarding Earnings Results for the Fourth Quarter and Year Ended December 31, 2009, dated February 25, 2010 Table of Contents NETEASE.COM, INC. /s/ Onward Choi Name: Onward Choi Title: Acting Chief Financial Officer Table of Contents Press Release]
[China Sunergy Co., Ltd. Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G84831 105** (CUSIP Number) December 31, 2009 [] Rule 13d-1(b) [ ] Rule 13d-1(c) [X ] Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of]
[Biostar Pharmaceuticals, Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operatingome of $16 $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) Biostar expects to report gross margin for 2009 of approximately 71%, anrease of 1200 basis-pointsmpared to 59% in 2008. Management anticipates unaudited operatingome, excluding non-cash charges, of approximately]
[Biostar Pharmaceuticals, Provides Preliminary 2009 Results: Revenue of $52 - $54 Million and Operatingome of $16 $17 million excluding non-cash charges XIANYANG, China, February 25, 2010 (Xinhua-PRNewswire-FirstCall) Biostar expects to report gross margin for 2009 of approximately 71%, anrease of 1200 basis-pointsmpared to 59% in 2008. Management anticipates unaudited operatingome, excluding non-cash charges, of approximately]
